Full-Time

Medical Science Liaison Rare Disease

Updated on 3/14/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Compensation Overview

$138.7k - $220kAnnually

Mid, Senior

Remote in USA

Candidates are preferred to be located near New Haven, CT; Boston, MA; or New York, NY.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced degree (MD, PharmD, PhD) in a scientific discipline or related field
  • 5 years of progressively responsible experience within the pharmaceutical or biotech industry
  • Focus on rare diseases, epilepsy, neurology or psychiatry is strongly preferred
  • Previous MSL experience desired
  • An equivalent combination of relevant education and experience may be considered
Responsibilities
  • Identifies and develops relationships with national and regional medical and scientific thought leaders, patient advocacy groups, and centers of excellence
  • Engages national and regional thought leaders to align interests, discuss research and medical information, and participate in scientific exchange and education
  • Provides research trial site support and investigator-initiated research proposal cultivation and facilitation
  • Develops and maintains scientific, clinical and therapeutic expertise for Acadia’s portfolio
  • Cross-functionally collaborates, following all compliance guidelines, with regional field leadership partners including Regional Business Leaders (RBL) and Account Business Managers (ABMs)
  • Provides strategic field insights
  • Identifies disease concepts and compound characteristics that can be leveraged into product differentiation
  • Provide appropriate scientific, clinical, and educational support for internal and external clients
  • Represents the company at specific continuing educational events, programs, medical meetings and conventions
  • Supports Commercial operations by participating in Speaker and Sales Representative Training
  • Partners with the internal departments to ensure accurate delivery of medical and scientific information
  • Performs other duties as assigned
Desired Qualifications
  • 7 years of progressively responsible experience in the medical, clinical, and/or pharmaceutical field for Sr. Medical Science Liaison
  • 3 years as an MSL for Sr. Medical Science Liaison
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's DAYBUE is now available for treating Rett syndrome in the U.S.
  • The partnership with Neuren Pharmaceuticals strengthens Acadia's position in the rare disease market.
  • Increased focus on personalized medicine benefits Acadia's tailored CNS disorder therapies.

What critics are saying

  • A class action lawsuit could lead to financial liabilities and reputational damage.
  • Increased competition in CNS treatments may impact Acadia's market share.
  • Reliance on partnerships poses risks if collaborations face challenges or fail.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline of small molecule drugs.
  • The company has a unique partnership with Stoke Therapeutics for RNA-based therapies.
  • Acadia's documentary series raises awareness for Rett syndrome, enhancing its community engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia